Abbott making a big India buy – The speculation that has been fuelling the shares of Piramal Healthcare over the past few days has been put to rest after Abbott Laboratories announced Friday that it will buy a unit of the Indian pharmaceutical company…more
Lots of Oncology. Rituxan: cutting lymphoma recurrence – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the disease…more And, some good news on sarcoma: An experimental drug from Ziopharm Oncology Inc. helped keep fast-growing sarcomas, lethal tumors that can grow to the size of basketballs, in check 77% longer than a standard treatment, a company-sponsored study found…more Plus, Amgen experimental drugs slow down some tumors.
Some side effects of popular cholesterol-lowering drugs? – Drugs to lower cholesterol and prevent heart disease, taken by millions of people worldwide, increase the risk of cataracts, kidney failure, muscle pain and liver dysfunction, a study of more than 2 million Britons found…more
Social Media Community/Facebook Moderation and Management. Our social media partners offer a range of services, including community moderation and platform design. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
The Doctor Won’t See You Now training.
JUST FOR FUN
It’s spring, and the weather’s fine. So, go on one of America’s Scenic Drives.
AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board